This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BG Medicine Appoints Dr. Paul Sohmer As Chief Executive Officer

WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has appointed Paul Sohmer, M.D., as its President & Chief Executive Officer and a member of its Board of Directors, effective immediately. Dr. Sohmer, who brings more than 25 years of experience leading the growth of commercial-stage companies focused on diagnostics, laboratory services, and medical devices, replaces Eric Bouvier as CEO.

"Paul Sohmer has a strong track record of building commercially successful diagnostic companies and we are excited to have him lead BG Medicine at this critical time," said Stephane Bancel, Executive Chairman of BG Medicine. "With two innovative diagnostic tests that aim to meet important needs in cardiovascular care and a sharpened focus on execution, we believe the pieces are in place to accelerate our commercial growth and deliver strong results for our shareholders."

Dr. Sohmer has led multiple high-growth companies in the areas of in vitro diagnostics and hospital-based and esoteric reference laboratory services. He served most recently as president and CEO of Viracor-IBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology and infectious disease testing. Previously, Sohmer was CEO of Orthocon, Inc., a developer, manufacturer and marketer of implantable medical products; and before that, served as interim CEO of Cylex, Inc. and CEO of Pathway Diagnostics Ltd. He was president and CEO of publicly traded Neuromedical Systems, Inc., before its acquisition by TriPath Imaging, Inc., and was TriPath's chairman, president and CEO before its acquisition by Becton, Dickinson and Company. Earlier in his career, Dr. Sohmer served as president and CEO of Genetrix, Inc., a genetic testing lab that was acquired by Genzyme Corporation. Dr. Sohmer holds a B.A. from Northwestern University and an M.D. from the Chicago Medical School.

"I am thrilled to be asked to lead BG Medicine, which is poised to bring major improvements to the quality and delivery of cardiovascular care through its innovative diagnostic tests for heart failure, and for the prediction of major cardiovascular events," Dr. Sohmer said. "The clinical case for widespread galectin-3 testing in heart failure continues to grow stronger; especially given the role it can play as part of a comprehensive strategy to reduce unplanned hospital readmissions for heart failure patients. CardioSCORE, which is now available in the EU, is expected to play an important role in identifying patients at high risk of a near-term cardiovascular events. Our challenge now is to unlock the clinical and commercial potential of the company's innovative diagnostic tests. Going forward we will work to enhance and leverage our assets to create a commercial engine that will allow us to grow and drive our margin."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs